{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:40:54Z","timestamp":1792762854242,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":232,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101409","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:05:11Z","timestamp":1787756711000},"page":"101409","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Clinical trajectories from first-line chemotherapy to best supportive care in unresectable pancreatic cancer: a 10-year real-world retrospective study"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1487-4676","authenticated-orcid":false,"given":"Kohei","family":"Nagata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Kawanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banri","family":"Ogino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Entani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iori","family":"Motoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiko","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kajiura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuto","family":"Tajiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2026.101409_bib0001","first-page":"1","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ctarc.2026.101409_bib0002","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2026.101409_bib0003","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2026.101409_bib0004","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","article-title":"Pancreatic cancer","volume":"395","author":"Mizrahi","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ctarc.2026.101409_bib0005","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJMoa1000678","article-title":"Early palliative care for patients with metastatic non-small-cell lung cancer","volume":"363","author":"Temel","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101409_bib0006","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/onco.13625","article-title":"Timing of palliative care referral before and after evidence from trials supporting early palliative care","volume":"26","author":"Hausner","year":"2021","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101409_bib0007","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40801-018-0137-x","article-title":"Clinical outcomes with first-line chemotherapy in a large retrospective study of patients with metastatic pancreatic cancer treated in a US community oncology setting","volume":"5","author":"Cartwright","year":"2018","journal-title":"Drugs-Real World Outcome."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101409_bib0008","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12885-018-5244-2","article-title":"Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer","volume":"19","author":"Blomstrand","year":"2019","journal-title":"BMC. Cancer"},{"issue":"12","key":"10.1016\/j.ctarc.2026.101409_bib0009","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7345","article-title":"Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as second or later-line treatment: a multicenter retrospective study","volume":"13","author":"Giordano","year":"2024","journal-title":"Cancer Med."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101409_bib0010","first-page":"171","article-title":"Real-world predictive models for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer","volume":"29","author":"Adamczuk-Nurzy\u0144ska","year":"2025","journal-title":"Contemp. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101409_bib0011","article-title":"Prognostic and clinicopathological significance of C-reactive protein to albumin ratio in patients with pancreatic cancer: a meta-analysis","volume":"18","author":"Xie","year":"2020","journal-title":"Dose Respons."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101409_bib0012","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40001-020-00444-z","article-title":"The ultimate preoperative C-reactive protein-to-albumin ratio is a prognostic factor for survival after pancreatic cancer resection","volume":"25","author":"van Wijk","year":"2020","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.ctarc.2026.101409_bib0013","doi-asserted-by":"crossref","first-page":"9626","DOI":"10.1038\/s41598-023-34962-7","article-title":"C-reactive protein\/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel","volume":"13","author":"Shirakawa","year":"2023","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101409_bib0014","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1200\/JCO.1983.1.11.710","article-title":"Analysis of survival by tumor response and other time-dependent covariates in clinical trials","volume":"1","author":"Anderson","year":"1983","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101409_bib0015","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1200\/JCO.2013.53.6995","article-title":"Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: a randomized phase III study (CONKO-003)","volume":"32","author":"Oettle","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101409_bib0016","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer previously treated with gemcitabine-based therapy (NAPOLI-1): a global phase 3 trial","volume":"387","author":"Wang-Gillam","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101409_bib0017","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1245\/s10434-016-5579-3","article-title":"Prognostic value of the CRP\/Alb ratio, a novel inflammation-based score in pancreatic cancer","volume":"24","author":"Liu","year":"2017","journal-title":"Ann. Surg. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101409_bib0018","first-page":"3252","article-title":"Clinicopathologic and prognostic significance of C-reactive protein\/albumin ratio in patients with solid tumors: an updated systematic review and meta-analysis","volume":"9","author":"Wu","year":"2018","journal-title":"Oncotarget"},{"issue":"43","key":"10.1016\/j.ctarc.2026.101409_bib0019","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000045329","article-title":"Associations of C-reactive protein\/albumin ratio with frailty and the risk of mortality: an observational study","volume":"104","author":"Xu","year":"2025","journal-title":"Medicine"},{"key":"10.1016\/j.ctarc.2026.101409_bib0020","doi-asserted-by":"crossref","DOI":"10.1177\/17588359261442386","article-title":"Predictors of prolonged progression-free survival in patients with unresectable or recurrent pancreatic cancer treated with nanoliposomal irinotecan with fluorouracil and folinic acid (NAPOLEON-2 study)","volume":"18","author":"Kawaguchi","year":"2026","journal-title":"Ther. Adv. Med. Oncol."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:44:17Z","timestamp":1791488657000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226003199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":20,"alternative-id":["S2468294226003199"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101409","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical trajectories from first-line chemotherapy to best supportive care in unresectable pancreatic cancer: a 10-year real-world retrospective study","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101409","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101409"}}